Indofarma Tbk PT banner

Indofarma Tbk PT
IDX:INAF

Watchlist Manager
Indofarma Tbk PT Logo
Indofarma Tbk PT
IDX:INAF
Watchlist
Price: 126 IDR Market Closed
Market Cap: Rp390.5B

Indofarma Tbk PT
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Indofarma Tbk PT
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Indofarma Tbk PT
IDX:INAF
EPS (Diluted)
-Rp95
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
EPS (Diluted)
Rp331
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
10%
Kalbe Farma Tbk PT
IDX:KLBF
EPS (Diluted)
Rp80
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
7%
Soho Global Health Tbk PT
IDX:SOHO
EPS (Diluted)
Rp47
CAGR 3-Years
19%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
EPS (Diluted)
-Rp33
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kimia Farma Tbk PT
IDX:KAEF
EPS (Diluted)
-Rp60
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Indofarma Tbk PT
Glance View

Market Cap
390.5B IDR
Industry
Pharmaceuticals

PT Indofarma Tbk is engaged in the pharmaceutical and healthcare businesses. The company is headquartered in Bekasi, Jawa Barat and currently employs 1,095 full-time employees. The company went IPO on 2001-04-17. The firm's business segment based on the products consists of the drug business segment and other medical equipment segment. The medical equipment segment consists of diagnostic and medical equipment. Its business segment based on geographical distribution area covers five regions consisting of Sumatra, Java, Kalimantan, Sulawesi and Bali, West Nusa Tenggara, and East Indonesia. Its products and services include generic drugs, over-the-counter and food, medical devices, non-medical devices and household health products. The firm carries out business activities to produce either alone or under cooperation for finished drug products, such as essential medicines, generic medicines with logos, generic medicines with trade names, traditional medicines, medical equipment, diagnostics, as well as food products, both related to health maintenance and improvement as well as health restoration.

INAF Intrinsic Value
168.37 IDR
Undervaluation 25%
Intrinsic Value
Price Rp126

See Also

What is Indofarma Tbk PT's EPS (Diluted)?
EPS (Diluted)
-95.2 IDR

Based on the financial report for Sep 30, 2025, Indofarma Tbk PT's EPS (Diluted) amounts to -95.2 IDR.

What is Indofarma Tbk PT's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-10%

Over the last year, the EPS (Diluted) growth was 58%. The average annual EPS (Diluted) growth rates for Indofarma Tbk PT have been -10% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett